Market Overview - As of June 12, the Shanghai Composite Index closed at 3402.66 points, with a slight increase of 0.34 points, representing a change of 0.01% [1] - The Shenzhen Component Index closed at 10234.33 points, down by 11.69 points, a decrease of 0.11% [1] - The ChiNext Index closed at 2067.15 points, up by 5.29 points, reflecting an increase of 0.26% [1] Trading Activity - A total of 128 A-shares had a turnover rate exceeding 20% on the same day, indicating significant trading activity [1] - Notably, C Haiyang and Zhongke Magnetic had turnover rates exceeding 50%, suggesting a high level of liquidity and interest in these stocks [1] Top Performing Stocks - C Haiyang (603382) had a closing price of 55.97 yuan with a turnover rate of 85.43% and a remarkable increase of 386.70% [1] - Zhongke Magnetic (301141) closed at 68.13 yuan, with a turnover rate of 67.96% and a gain of 3.20% [1] - Yingsite (301622) closed at 97.32 yuan, achieving a turnover rate of 60.53% and a rise of 20.00% [1] - Jiangnan New Materials (603124) closed at 48.20 yuan, with a turnover rate of 57.58% and an increase of 4.83% [1] - Xiongdi Technology (300546) closed at 34.41 yuan, with a turnover rate of 56.64% and a gain of 7.20% [1] Additional Notable Stocks - Kangliyuan (301287) closed at 50.52 yuan, with a turnover rate of 48.58% and a slight decrease of 0.26% [1] - Qingmu Technology (301110) closed at 72.42 yuan, achieving a turnover rate of 46.33% and a rise of 20.00% [1] - Baixinglong (833075) closed at 46.99 yuan, with a turnover rate of 44.54% and an increase of 29.99% [1] - Hengbao Co., Ltd. (002104) closed at 11.82 yuan, with a turnover rate of 44.51% and a gain of 2.34% [1] - Guokang Biochemical (300804) closed at 61.10 yuan, with a turnover rate of 42.76% and a slight increase of 1.08% [1]

Market Overview - The Shanghai Composite Index rose by 0.52% on June 11, with 28 out of 33 sectors experiencing gains, led by the non-ferrous metals and agriculture sectors, which increased by 2.21% and 2.02% respectively [1] - The pharmaceutical and biotechnology sector was the biggest loser, declining by 0.41% [1] Capital Flow Analysis - The net inflow of capital in the two markets was 1.506 billion yuan, with 14 sectors seeing net inflows [1] - The non-bank financial sector had the largest net inflow of 4.469 billion yuan, rising by 1.90%, followed by the automotive sector with a net inflow of 2.750 billion yuan and a daily increase of 1.70% [1] Pharmaceutical and Biotechnology Sector - The pharmaceutical and biotechnology sector saw a net outflow of 2.629 billion yuan, with 475 stocks in the sector; 157 stocks rose while 306 fell [2] - The top three stocks with the highest net inflow were Kangyuan Pharmaceutical (2.42 billion yuan), Rundu Co., Ltd. (1.56 billion yuan), and Baiyang Pharmaceutical (840.855 million yuan) [2] - The stocks with the largest net outflows included Hengrui Medicine (1.53 billion yuan), Yong'an Pharmaceutical (1.36 billion yuan), and Kailai Pharmaceutical (1.27 billion yuan) [2] Top Gainers in Pharmaceutical Sector - Kangyuan Pharmaceutical: +9.97%, turnover rate 8.65%, net inflow 241.8664 million yuan [4] - Rundu Co., Ltd.: +9.98%, turnover rate 14.71%, net inflow 155.7670 million yuan [4] - Baiyang Pharmaceutical: +10.33%, turnover rate 8.13%, net inflow 84.0855 million yuan [4] Top Losers in Pharmaceutical Sector - Hengrui Medicine: -0.76%, turnover rate 0.59%, net outflow -153.0498 million yuan [4] - Yong'an Pharmaceutical: -8.87%, turnover rate 24.11%, net outflow -135.7947 million yuan [4] - Kailai Pharmaceutical: -2.35%, turnover rate 1.71%, net outflow -127.0972 million yuan [4]

Group 1: Company Strategy and Development - The company focuses on health sectors, particularly cardiovascular, digestive, analgesic, and anesthetic medications, aiming to enhance its formulation industry and maintain its unique drug formulations and controlled-release technologies [3][6]. - Plans to accelerate the development and market entry of high-barrier generics and innovative drugs while expanding its international business through a global formulation production platform [3][6]. - The company aims to build a high-end active pharmaceutical ingredient (API) and intermediate manufacturing base with a focus on green and intelligent manufacturing technologies [4][6]. Group 2: Financial Performance and Challenges - The company experienced a significant decline in revenue in 2024, primarily due to national procurement policies leading to a substantial drop in sales prices of key formulation products [5][7]. - The decline in revenue was also influenced by competitive pressures in the domestic and international markets affecting the sales prices of major API products [5][7]. - Cumulative cash dividends since the company's listing in 2018 have reached CNY 496 million, reflecting a commitment to shareholder returns [8]. Group 3: Market Expansion and Partnerships - The company has successfully obtained market access qualifications for certain specialty APIs in major markets, including the WHO, the USA, the EU, and Japan, and is actively exploring emerging markets in the Middle East, South Asia, Southeast Asia, and South America [4][6]. - Established long-term stable partnerships with numerous large formulation manufacturers, positioning itself as a leading supplier of antihypertensive APIs globally [4][6]. Group 4: Research and Development Focus - The company continues to focus on both innovative and generic drug development, with recent submissions for new drug applications and multiple product registrations for generics [9]. - Future R&D efforts will concentrate on health-related fields, leveraging core technological advantages in controlled-release formulations and APIs [9].

Group 1 - The Artemisinin concept sector rose by 1.17%, ranking 7th among concept sectors, with six stocks increasing in value, including Fosun Pharma, Zhejiang Medicine, and Haizheng Pharmaceutical, which rose by 5.23%, 4.94%, and 1.54% respectively [1] - The leading stocks in terms of net inflow of main funds were Zhejiang Medicine, Fosun Pharma, Baiyun Mountain, and Haizheng Pharmaceutical, with net inflows of 856.29 million, 545.22 million, 103.85 million, and 52.54 million respectively [1] - The main fund inflow rates for Zhejiang Medicine, Baiyun Mountain, and Fosun Pharma were 7.58%, 7.56%, and 3.62% respectively [2] Group 2 - The top gainers in the concept sector included pork, chicken farming, innovative drugs, and animal vaccines, while the top losers included controllable nuclear fusion and decelerators [1] - The overall market performance showed a mixed trend, with some sectors experiencing significant gains while others faced declines [1] - The trading volume and turnover rates varied among the stocks, indicating differing levels of investor interest and activity [2][3]

证券代码：002923 证券简称：润都股份 公告编号：2025-025 珠海润都制药股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： ? 会议召开时间：2025 年 06 月 06 日（星期五）15:00-17:00 会议召开时间：2025 年 06 月 06 日（星期五）15:00-17:00 会议召开地点：价值在线（www.ir-online.cn） 会议召开方式：网络互动方式 珠海润都制药股份有限公司（以下简称"公司"）已于 2025 年 04 月 29 日 在巨潮资讯网上披露了《2024 年年度报告全文》及《2024 年年度报告摘要》。 为便于广大投资者更加全面深入地了解公司经营业绩、发展战略等情况，公司定 于 2025 年 06 月 06 日（星期五） （www.ir-online.cn） 举办珠海润都制药股份有限公司 2024 年度网上业绩说明会，与投资者进行沟通 和交流，广泛听取投资者的意见和建议。 一、说明会召开的时间、地点和方式 五、其他事项 本次业绩说明会召开后，投资者可以通过价值在线（www.ir-online ...

证券代码：002923 证券简称：润都股份 公告编号：2025-025 珠海润都制药股份有限公司 关于举办2024年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 珠海润都制药股份有限公司（以下简称"公司"）已于 2025 年 04 月 29 日 在巨潮资讯网上披露了《2024 年年度报告全文》及《2024 年年度报告摘要》。 为便于广大投资者更加全面深入地了解公司经营业绩、发展战略等情况，公司定 于 2025 年 06 月 06 日（星期五）15:00-17:00 在"价值在线"（www.ir-online.cn） 举办珠海润都制药股份有限公司 2024 年度网上业绩说明会，与投资者进行沟通 会议召开时间：2025 年 06 月 06 日（星期五）15:00-17:00 会议召开方式：网络互动方式 会议召开地点：价值在线（www.ir-online.cn） 会议问题征集：投资者可于 2025 年 06 月 06 日 前 访 问 网 址 https://eseb.cn/1oDYC6OhcyY 或使用微信扫描下方小程序码进 ...

Core Viewpoint - The company, Zhuhai Runduo Pharmaceutical Co., Ltd., has announced its profit distribution plan for the fiscal year 2024, which includes a cash dividend distribution to shareholders [1][2]. Summary by Sections Profit Distribution Plan - The profit distribution plan was approved at the annual shareholders' meeting held on May 20, 2025, with a total share capital of 334,893,286 shares as the basis for distribution [1][2]. - The company will distribute a cash dividend of 1.50 RMB per 10 shares (including tax), totaling approximately 50,233,992.90 RMB [1][2]. Adjustments and Implementation - If there are changes in share capital due to share buybacks before the implementation of the distribution, the company will adjust the basis for distribution accordingly, maintaining the same distribution ratio [1]. - The board of directors has been authorized to oversee the specific implementation of this profit distribution [1]. Taxation Details - For investors holding shares through the Hong Kong market, the cash dividend will be 1.35 RMB per 10 shares after tax [2]. - Different tax rates will apply based on the holding period of shares, with specific provisions for individual and institutional investors [2]. Key Dates - The record date for the distribution is set for May 29, 2025, and the ex-dividend date is May 30, 2025 [2][3]. Distribution Method - Cash dividends will be directly credited to the shareholders' accounts through their securities companies or other custodians [3].

本次利润分配方案公布后至实施前，若股本由于股份回购等发生变化时，公 司则以未来实施分配方案时股权登记日扣除回购股份后的股数为基数，按照分配 比例不变的原则进行相应调整。同时，董事会提请股东大会授权董事会、管理层 负责本次利润分配的具体实施事宜。 2024 年年度股东大会决议公告已于 2025 年 05 月 21 日在公司指定信息披露 媒体《证券时报》《证券日报》《中国证券报》《上海证券报》和巨潮资讯网 （www.cninfo.com.cn）进行披露。 证券代码：002923 证券简称：润都股份 公告编号：2025-024 珠海润都制药股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 珠海润都制药股份有限公司（以下简称"公司"）2024 年度权益分派方案已 获 2025 年 05 月 20 日召开的 2024 年年度股东大会审议通过，现将权益分派事宜 公告如下： 一、股东大会审议通过利润分配方案的情况 1、公司于 2025 年 05 月 20 日召开的 2024 年年度股东大会审议通过了《2024 年度利润分配预案》 ...

Group 1 - Huiyu Pharmaceutical's subsidiary received drug registration certificate for Carboxymethyl Sodium Injection, which is used for treating bleeding diseases in various medical fields [1] - Baihe Co., Ltd. announced a plan for a director to reduce holdings by up to 424,000 shares, representing 0.6625% of the total share capital [1] - Kingood Co., Ltd. received a notification from a global leading automaker for a wheel project, expected to start mass production in 2026 with a lifecycle of 10 years [1][2] Group 2 - Wanhua Chemical plans to repurchase shares worth between 300 million and 500 million yuan, with a maximum repurchase price of 99.36 yuan per share [2] - Warner Pharmaceutical's subsidiary received approval for Acetylcysteine raw material drug, primarily used for treating respiratory diseases [3] - ST Mingcheng plans to publicly transfer 45% equity of its subsidiary, aiming to optimize asset structure [4] Group 3 - Qixia Construction announced a plan to reduce up to 31.5 million shares, accounting for 3% of total share capital [5][6] - Zhejiang Rongtai intends to invest 20 million yuan to establish a wholly-owned subsidiary focused on intelligent robotics [7] - Yuandong Biological received drug registration for Chloral Hydrate Enema, used for sedation and seizure control in children [9] Group 4 - Jiemai Technology's subsidiary signed a strategic cooperation agreement with a solid-state battery company to produce high-safety composite conductive materials [10] - Xianju Pharmaceutical received drug registration for Progesterone Soft Capsules, used for treating functional disorders due to luteal deficiency [11] - Lanhua Kecai's subsidiary reported a temporary production halt, with the resumption date yet to be determined [13] Group 5 - Sinopharm Modern's subsidiary received drug registration for Tocilizumab Tablets, used for treating rheumatoid arthritis and other conditions [15] - Shanghai Bank announced the resignation of its vice president due to organizational adjustments [17] - Shanghai Pharmaceutical's Ephedrine Injection passed the consistency evaluation for generic drugs [19] Group 6 - Rundu Co., Ltd. received drug registration for Amlodipine and Olmesartan Tablets, aimed at treating hypertension [21] - Zhong'an Technology announced that 61 million shares held by its controlling shareholder will be auctioned [23] - Shanghai Washba plans to purchase patent assets and establish two subsidiaries focused on hydrogen energy and solid-state battery technologies [25] Group 7 - Nuo Cheng Jianhua's new drug Tafasitamab received approval for treating relapsed/refractory diffuse large B-cell lymphoma [26] - Benli Technology plans to use up to 200 million yuan of idle funds for cash management and financial investments [28] - Taiji Co., Ltd. intends to use 60 million yuan of idle funds to purchase financial products [29] Group 8 - Haishi Co. announced that its innovative drug Anreke Fen Injection received drug registration for treating postoperative pain [32] - Yulong Co. will have its stock delisted on May 27, 2025, following a decision by the Shanghai Stock Exchange [36] - Weifu High-Tech plans to establish a joint venture with Shanghai Baolong Automotive Technology [38] Group 9 - Xichang Electric Power expects a net profit reduction of approximately 5.4 million yuan due to adjustments in the time-of-use electricity pricing mechanism [39] - Alter signed a contract worth 6.8 billion yen for the development and procurement of large truck EV kits [41] - Zhonglian Heavy Industry plans to acquire controlling stakes in its financing leasing subsidiary through public bidding [42] Group 10 - Sanyou Medical's executive plans to reduce holdings by up to 1.44% of the company's shares [43] - Hangyang Co. plans to establish a subsidiary for large modular cryogenic equipment manufacturing with an estimated investment of 557 million yuan [44] - FAW Fuwi received a notification for a dashboard project from a well-known new energy brand, with total sales expected to reach 1.06 billion yuan [45]

证券代码：002923 证券简称：润都股份 公告编号：2025-023 珠海润都制药股份有限公司 珠海润都制药股份有限公司（以下简称"公司"或"本公司"）近日收到国 家药品监督管理局签发的《药品注册证书》。现将有关情况公告如下： 一、药品基本情况 药品名称：奥美沙坦酯氨氯地平片（以下简称"本品"） 剂型：片剂 申请事项：药品注册(境内生产) 规格：每片含奥美沙坦酯20mg和苯磺酸氨氯地平5mg（按C₂₀H₂₅ClN₂O₅计） 注册分类：化学药品4类 受理号：CYHS2400029 证书编号：2025S01360 关于奥美沙坦酯氨氯地平片获得药品注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 药品注册标准编号：YBH09492025 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。质量标准、说明书、 标签及生产工艺照所附执行。 二、药品的适应症 本品适用于治疗原发性高血压。本固定剂量复方适用于单用奥美沙坦酯或单 用氨氯地平治疗血压控制效果不佳的成人患者。 三、对公司的影响及风 ...